Opioid Quota Reform Act
USA115th CongressS-2535| Senate
| Updated: 6/19/2018
Richard J. Durbin
Democratic Senator
Illinois
Cosponsors (4)
Judiciary Committee
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Opioid Quota Reform Act This bill amends the Controlled Substances Act to require the Drug Enforcement Administration (DEA) to consider additional factors—the impact on overall public health and rates of diversion, abuse, and overdose deaths—in setting and adjusting production and manufacturing quotas for fentanyl, oxycodone, hydrocodone, oxymorphone, and hydromorphone. Additionally, if the DEA increases the production quota of fentanyl, oxycodone, hydrocodone, oxymorphone, or hydromorphone, then it must explain why the public health benefits of increasing the quota outweigh the consequences of potential diversion.
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on the Judiciary. (text of measure as introduced: CR S1632)
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 473.
Crime and Law Enforcement
Administrative law and regulatory proceduresCongressional oversightDepartment of JusticeDrug, alcohol, tobacco useDrug trafficking and controlled substancesHealth information and medical records
Opioid Quota Reform Act
USA115th CongressS-2535| Senate
| Updated: 6/19/2018
Opioid Quota Reform Act This bill amends the Controlled Substances Act to require the Drug Enforcement Administration (DEA) to consider additional factors—the impact on overall public health and rates of diversion, abuse, and overdose deaths—in setting and adjusting production and manufacturing quotas for fentanyl, oxycodone, hydrocodone, oxymorphone, and hydromorphone. Additionally, if the DEA increases the production quota of fentanyl, oxycodone, hydrocodone, oxymorphone, or hydromorphone, then it must explain why the public health benefits of increasing the quota outweigh the consequences of potential diversion.
Suggested Questions
Get AI-generated questions to help you understand this bill better
Timeline
Introduced in Senate
Read twice and referred to the Committee on the Judiciary. (text of measure as introduced: CR S1632)
Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
Committee on the Judiciary. Reported by Senator Grassley with an amendment in the nature of a substitute. Without written report.
Placed on Senate Legislative Calendar under General Orders. Calendar No. 473.
Richard J. Durbin
Democratic Senator
Illinois
Cosponsors (4)
Judiciary Committee
Crime and Law Enforcement
- Introduced
- In Committee
- On Floor
- Passed Chamber
- Enacted
Administrative law and regulatory proceduresCongressional oversightDepartment of JusticeDrug, alcohol, tobacco useDrug trafficking and controlled substancesHealth information and medical records